United States Patent 7,470,506: Claim Scope, Claim Construction Drivers, and HIV Protease-Resistance Combination Landscape
What does US 7,470,506 claim cover?
United States Drug Patent 7,470,506 claims a method-of-treatment for an HIV-infected mammal that has developed resistance to HIV treatments, using (1) a compound defined by a structural formula and (2) at least one antiviral agent selected from a defined protease-inhibitor set.
Core claim element (Claim 1)
Claim 1 is structured as a three-step method:
- Determine resistance: determine whether the mammal “has developed resistance to HIV treatments.”
- Administer the defined compound: administer an “effective amount” of a compound of the formula where:
- X is oxygen
- R5 is isobutyl
- Ar is substituted phenyl
- Administer additional antiviral agent(s): administer at least one antiviral agent selected from:
- ritonavir
- indinavir
- amprenavir
- saquinavir
- Outcome: whereby the HIV-infected mammal is treated.
Claim 1 is a combination method, not a compound-alone method
The claim requires both:
- the specific substituted-phenyl / isobutyl / oxygen-linked compound (formula constrained), and
- at least one protease inhibitor from the named group.
Because the claim is a method claim, infringement hinges on use in a treated patient setting that satisfies both the compound definition and the combination requirement.
How broad are the substituent and positional limitations?
Claims 2–5 materially tighten Claim 1 by narrowing the identity and substitution position of Ar. Claim 1 leaves Ar broadly “substituted phenyl,” but the dependent claims define specific substitution positions and substituent examples.
Positional narrowing (Claims 2–4)
- Claim 2: Ar is substituted at the para-position.
- Claim 3: Ar is substituted at the meta-position.
- Claim 4: Ar is substituted at the ortho-position.
These dependent claims create a positional ladder:
- Claim 1: broad substituted phenyl
- Claim 2–4: substituted phenyl limited by substitution location
Example substituents (Claim 5)
Claim 5 sets Ar options from a defined list:
- para-aminophenyl
- para-toluoyl
- para-methoxyphenyl
- meta-methoxyphenyl
- meta-hydroxymethylphenyl
This is a strong narrowing device. It is not merely “any para-substituted phenyl”; it is a defined subset across positional classes (para and meta) with named substituents.
Practical claim-coverage implication
- If a competitor uses a non-enumerated substituent on the phenyl ring, it may fall outside Claim 5 but still potentially within Claim 1 (depending on how “substituted phenyl” is construed and whether the structural formula in Claim 1 is interpreted as covering the full phenyl substitution space).
- If a competitor uses one of the enumerated substituents, the case for coverage under dependent claims strengthens.
What patient and resistance constraints limit Claim 1?
Claim 1 requires a resistance-defined population; dependent claims expand the resistance framing.
Wild-type vs mutant definitions (Claims 6–8)
- Claim 6: HIV-infected mammal is infected with wild-type HIV.
- Claim 7: infected with mutant HIV with at least one protease mutation.
- Claim 8: infected with mutant HIV with at least one reverse transcriptase mutation.
Resolution of an internal tension: Claim 6 vs “resistance” requirement
Claim 1 already says the mammal has “developed resistance to HIV treatments.” Claim 6 then adds “wild-type HIV.” On its face, that reads as two different resistance paradigms:
- resistance may be present through treatment history (not necessarily linked to a detectable viral genotype), or
- the patent includes a broader resistance determination step that is not strictly confined to having protease or reverse transcriptase mutations.
From a claim-scope perspective, Claim 6 can capture settings where resistance is determined phenotypically or clinically, even if the sampled virus is wild-type as to targeted protease/reverse transcriptase mutation categories.
How does Claim 9 narrow the antiviral combination?
- Claim 9: the at least one antiviral agent is ritonavir.
This narrows Claim 1’s four-drug list to ritonavir only.
Combination scope
- Claim 1: combination with any of ritonavir / indinavir / amprenavir / saquinavir
- Claim 9: combination with ritonavir
So ritonavir-based regimens fall within both Claim 1 and Claim 9 if the compound definition is met.
What is the likely patent landscape around this claim set?
Because the claim is a use/combination method defined by:
- a structurally constrained compound class (X oxygen, R5 isobutyl, substituted phenyl Ar), and
- a protease inhibitor combination list (ritonavir, indinavir, amprenavir, saquinavir),
the competitive landscape clusters into three overlapping zones.
Zone 1: Protease inhibitor co-therapy patents (ritonavir/indinavir/amprenavir/saquinavir)
These agents have extensive patent families around:
- pharmaceutical compositions
- dosing and regimen claims
- resistance management concepts
Where 7,470,506 differs is that it does not claim the protease inhibitor itself; it claims a specific compound class + selection of at least one protease inhibitor in a resistance-defined patient.
Zone 2: HIV resistance and genotype-guided therapy methods
Claim 7 and Claim 8 specifically reference:
- protease mutation presence
- reverse transcriptase mutation presence
This language aligns with a broader industry trend: tailoring therapy based on mutation patterns. Even if earlier patents claimed mutation-guided regimens generally, a claim like 7,470,506 is more likely to be vulnerable or strengthened based on whether the compound class and the specific combination are novel relative to those teachings.
Zone 3: Structural-compound families covering substituted phenyl and isobutyl-linked oxygen compounds
For a landscape assessment, the key question is whether the “formula” compound class is itself covered by earlier or later patents, and whether those patents also claim combination use with protease inhibitors.
In a typical HIV small-molecule program, patents exist for:
- the compound structure and intermediates
- prodrugs/analogues
- formulation
- and later method-of-use claims for resistant disease
Claim 1’s method phrasing suggests the patent is likely part of an ecosystem where the compound family is anchored by structure claims, and the therapeutic positioning is added via combination method claims.
Where are the enforceability pressure points in the claim text?
The claim set has clear pressure points that drive claim interpretation and validity/infringement risk.
1) “Compound of the formula” boundary
Claim 1 depends on a formula with specific constraints:
- X = oxygen
- R5 = isobutyl
- Ar = substituted phenyl
For infringement, a challenger focuses on whether the accused product meets every structural constraint. If a competing compound changes any of these, it may exit Claim 1.
For validity, a challenger attacks novelty/obviousness by citing prior art teaching similar structural substitutions and therapeutic combinations.
2) “At least one antiviral agent selected from…” list
The claim uses an open-ended combination requirement:
- Any one of the four listed antivirals can satisfy the “at least one” element.
This increases infringement coverage for ritonavir-, indinavir-, amprenavir-, or saquinavir-based regimens.
But the claim remains closed to other antivirals. A regimen using only other agents (for example, nucleoside reverse transcriptase inhibitors or other classes not in the list) does not satisfy the “selected from” element.
3) Resistance determination step (i)
The step “determining whether the mammal has developed resistance” may be attacked if interpreted as non-limiting or if it is considered routine clinical management. Still, as written, it is a claim step.
In litigation, this element can be decisive depending on how the fact pattern is framed:
- Was resistance actually determined?
- Does the accused provider documentation or clinical protocol show the “determining” step?
4) Wild-type HIV inclusion (Claim 6)
Claim 6 broadens the patient category. If an opponent argues that resistance implies mutant genotype, Claim 6 supports a counter-position that resistance can be determined without requiring protease or reverse transcriptase mutations as a precondition.
This affects how narrowly a court may construe the “resistance” concept.
Claim chart: scope summary by dependency
| Claim |
Additional limitation over Claim 1 |
Effect on coverage |
| 1 |
Resistance determination; compound formula constraints (X oxygen, R5 isobutyl, Ar substituted phenyl); co-administer antiviral from {ritonavir, indinavir, amprenavir, saquinavir} |
Baseline method scope; broad on Ar beyond “substituted phenyl,” broad on which listed antiviral |
| 2 |
Ar substituted at para position |
Narrows positional scope of Ar |
| 3 |
Ar substituted at meta position |
Narrows positional scope of Ar |
| 4 |
Ar substituted at ortho position |
Narrows positional scope of Ar |
| 5 |
Ar is one of specific substituted phenyl examples |
Strongest Ar narrowing; enumerated substituents |
| 6 |
Patient infected with wild-type HIV |
Adds a patient category distinct from mutant-only scenarios |
| 7 |
Patient infected with mutant HIV with at least one protease mutation |
Genotype-guided narrowing (protease) |
| 8 |
Patient infected with mutant HIV with at least one reverse transcriptase mutation |
Genotype-guided narrowing (RT) |
| 9 |
Antiviral is ritonavir |
Narrows co-therapy to ritonavir |
What does this mean for competitive R&D and freedom-to-operate positioning?
1) Compound design strategy risk
If a competitor develops a molecule with:
- X not oxygen, or
- R5 not isobutyl, or
- Ar not a substituted phenyl within the formula boundary,
it can avoid Claim 1 at the structural element level.
If the structure matches, the key next lever is whether the regimen includes at least one of the four listed protease inhibitors.
2) Regimen selection is a major control point
Because Claim 1 requires co-administration of at least one listed antiviral, design-around can occur by:
- avoiding combinations with the listed protease inhibitors in a manner that does not meet “selected from” requirements
- or using a regimen where the accused therapeutic use does not satisfy the claim’s method steps.
For example, a regimen using other drug classes without ritonavir/indinavir/amprenavir/saquinavir would not meet the “selected from” element of Claim 1.
3) Patient selection and documentation
If a provider does not “determine resistance” as a step tied to the claimed treatment, the method claim may be harder to prove. Claim 1’s step (i) makes the clinical workflow and documentation relevant.
Key Takeaways
- US 7,470,506 claims a method of treating resistant HIV using a structurally constrained compound (X oxygen, R5 isobutyl, Ar substituted phenyl) plus at least one protease inhibitor from ritonavir/indinavir/amprenavir/saquinavir.
- Dependent claims narrow Ar by position (para/meta/ortho) and enumerate specific Ar substituents (para-aminophenyl, para-toluoyl, para-methoxyphenyl, meta-methoxyphenyl, meta-hydroxymethylphenyl).
- Patient genotype framing covers both wild-type and mutant HIV scenarios, including mutants with protease or reverse transcriptase mutations.
- Ritonavir monotherapy as the co-therapy is explicitly covered (Claim 9), while other antivirals outside the defined list are not encompassed by the claim’s combination element.
- Landscape pressure concentrates on structure-variant freedom (does the accused compound meet X/R5/Ar constraints) and regimen composition (does the clinical use include one of the four listed protease inhibitors).
FAQs
1) Is US 7,470,506 limited to ritonavir-only regimens?
No. Claim 1 allows at least one antiviral selected from ritonavir, indinavir, amprenavir, or saquinavir. Ritonavir-only is covered by Claim 9.
2) Does Claim 1 require a specific HIV mutation pattern?
Claim 1 requires resistance to HIV treatments. Claims 7 and 8 add mutation-specific scenarios (protease or reverse transcriptase), but Claim 6 covers wild-type HIV.
3) Can a different substituent on the phenyl ring avoid the patent?
It can avoid the narrow dependent claims (like Claim 5), but Claim 1 broadly covers “substituted phenyl” Ar within the formula constraint.
4) What is the strongest claim element for design-around?
Meeting the structural formula constraints (X oxygen, R5 isobutyl, Ar substituted phenyl) and the requirement to co-administer at least one of the four listed protease inhibitors.
5) Is this a compound patent or a method patent?
The provided claims are method-of-treatment claims, requiring both the defined compound use and the defined combination co-therapy.
References (APA)
[1] United States Patent 7,470,506. Claims 1–9 (as provided by user).
